产品
编 号：F311007
分子式：C19H19N5O
分子量：333.39
分子式：C19H19N5O
分子量：333.39
产品类型
规格
价格
是否有货
5mg
480
In-stock
10mg
816
In-stock
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 301326-22-7
产品详情
生物活性：
CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR).CH-223191 inhibits TCDD-mediated nuclear translocation and DNA binding of AhR, and inhibits TCDD-induced luciferase activity with an IC50 of 0.03 μM.
体内研究：
CH-223191 (10 mg/kg; once a day; 25 days) suppresses cytochrome P450 1A1 expression and the intrahepatocyte fat content in liver, reduces activity of AST and ALT in TCDD-treated mice.Animal Model:Male ICR mice (6 weeks old)
Dosage:10 mg/kg
Administration:10 mg/kg; once a day; 25 days
Result:Prevented TCDD-elicited cytochrome P450 induction, liver toxicity, and wasting syndrome in mice.
体外研究：
CH-223191 (0.1-10 μM; pre-treated 1 hour)inhibits TCDD-causedcytochrome P450 1A1 mRNA expression in a in dose-dependent manner.CH-223191 (0.1-10 μM; pre-treated 1 hour) causes a concentration-dependent inhibition of TCDD-induced cytochrome P450 enzyme activity.
CH-223191 is a potent and specific antagonist of aryl hydrocarbon receptor (AhR).CH-223191 inhibits TCDD-mediated nuclear translocation and DNA binding of AhR, and inhibits TCDD-induced luciferase activity with an IC50 of 0.03 μM.
体内研究：
CH-223191 (10 mg/kg; once a day; 25 days) suppresses cytochrome P450 1A1 expression and the intrahepatocyte fat content in liver, reduces activity of AST and ALT in TCDD-treated mice.Animal Model:Male ICR mice (6 weeks old)
Dosage:10 mg/kg
Administration:10 mg/kg; once a day; 25 days
Result:Prevented TCDD-elicited cytochrome P450 induction, liver toxicity, and wasting syndrome in mice.
体外研究：
CH-223191 (0.1-10 μM; pre-treated 1 hour)inhibits TCDD-causedcytochrome P450 1A1 mRNA expression in a in dose-dependent manner.CH-223191 (0.1-10 μM; pre-treated 1 hour) causes a concentration-dependent inhibition of TCDD-induced cytochrome P450 enzyme activity.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备